Harness Therapeutics nominates drug candidate for Huntington’s
Harness Therapeutics has announced the nomination of HRN001 as its lead drug candidate for Huntington’s disease (HD).
The company has also formed a clinical advisory board to support the programme’s advancement towards clinical evaluation.
Despite significant advances in understanding HD disease biology, there are currently no approved disease-modifying treatments available.
HD is caused by the expansion of CAG repeats in the huntingtin (HTT) gene. Ongoing somatic expansion of these repeats is now recognised as a key driver of disease onset and progression. FAN1 nuclease has emerged as one of the most compelling targets to suppress somatic expansion, demonstrating the strongest genetic association to disease onset in genome-wide association studies.
Harness’ first-in-class candidate HRN001 is a potent and specific antisense oligonucleotide targeting FAN1, designed to drive controlled upregulation of this key DNA repair nuclease. It leverages Harness’proprietary MISBA (microRNA site blocking ASO) platform, which enables precise upregulation of target protein levels without risk of over-expression.
HRN001 has demonstrated robust upregulation of FAN1 and slowing of somatic expansion in models of HD, as well as favourable PK and tolerability characteristics.
Dr Jan Thirkettle, CEO of Harness Therapeutics, commented: “The nomination of HRN001 represents a pivotal milestone for Harness and underscores our commitment to the Huntington’s disease community. By precisely upregulating FAN1, a target with compelling genetic validation in delaying disease onset, HRN001 represents a differentiated, first-in-class therapeutic approach for addressing somatic expansion, a fundamental driver of disease progression.
“The formation of a Clinical Advisory Board brings deep clinical and translational expertise to the programme. The CAB will work closely with Harness as we advance HRN001 towards the clinic and seek to deliver a truly disease-modifying therapy for patients and families living with Huntington’s disease.”
